Good to see the report make this comment, which is one of the reasons I think it's such a delectable stock -
'Unlike many emerging biotechnology companies with a promising
therapeutic product line requiring numerous costly clinical trials in order to
prove therapeutic efficacy for a specific indication, we see Cynata’s novel
stem cell production platform Cymerus™ as having less risk because the
potential clinical utility of MSCs has already been established in a variety of
therapeutic applications.'
Ann: SeeThruEquity Initiates Cynata Reasearch Coverage, page-24
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CYP (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.0¢ |
Change
0.020(7.41%) |
Mkt cap ! $52.09M | |||
| Open | High | Low | Value | Volume |
| 27.5¢ | 29.0¢ | 27.0¢ | $12.06K | 43.32K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 5825 | 27.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 29.0¢ | 4998 | 1 |
View Market Depth
| Last trade - 16.10pm 03/07/2024 (20 minute delay) ? |
| CYP (ASX) Chart |